Joshua Oglehart, APRN
Psychiatric/Mental Health · Cincinnati, OHNPI 1811338999
Payments from drug & device makers
Across 397 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$1K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$949
- Johnson & Johnson$861
- Neurocrine Biosciences, Inc.$832
- Alkermes, Inc.$509
- plus $3K from 12 others
What the payments were for
- Food & beverage$8,04598%
- Education$2012%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 46 | $1,480 |
| AbbVie | 63 | $1,025 |
| Otsuka America Pharmaceutical, Inc. | 41 | $949 |
| Johnson & Johnson | 56 | $861 |
| Neurocrine Biosciences, Inc. | 27 | $832 |
| Alkermes, Inc. | 41 | $509 |
| Lundbeck LLC | 23 | $501 |
| Axsome Therapeutics, Inc. | 16 | $356 |
| Vanda Pharmaceuticals Inc. | 12 | $353 |
| E.r. Squibb & Sons, L.L.C. | 6 | $306 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $286 |
| Supernus Pharmaceuticals, Inc. | 18 | $219 |
| Luye Pharma (USA) Ltd. | 9 | $200 |
| Indivior Inc. | 6 | $195 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Noven Therapeutics, LLC | 3 | $54 |
| Sunovion Pharmaceuticals Inc. | 4 | $42 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$696
- ARISTADA$477
- INGREZZA$378
- ABILIFY MAINTENA$370
- ABILIFY ASIMTUFII$370
- INVEGA SUSTENNA$252
- VRAYLAR$245
- ERZOFRI EXTENDED-RELEASE$129
- SUBLOCADE$125
- COBENFY$121
- INVEGA TRINZA$121
- ARISTADA INITIO$119
- Fanapt$104
How this compares
$8,246 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 161 | $539,740 |
| Austedo XrDeutetrabenazine | 46 | $428,429 |
| Invega TrinzaPaliperidone Palmitate | 25 | $269,630 |
| Abilify MaintenaAripiprazole | 65 | $170,199 |
| VraylarCariprazine Hcl | 119 | $161,072 |
| LybalviOlanzapine/Samidorphan Malate | 34 | $57,178 |
| UzedyRisperidone | 15 | $46,641 |
| AuvelityDextromethorphan Hbr/Bupropion | 42 | $39,640 |
| RexultiBrexpiprazole | 26 | $35,358 |
| Paliperidone ErPaliperidone | 82 | $26,948 |
| Risperdal ConstaRisperidone Microspheres | 20 | $25,414 |
| Risperidone ErRisperidone Microspheres | 21 | $22,116 |
| Aripiprazole | 203 | $15,832 |
| Clozapine | 72 | $11,982 |
| TrintellixVortioxetine Hydrobromide | 15 | $11,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $861 | $834,784206 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy | $1,480 | $475,06961 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $949 | $205,55791 claims |
| AbbVieVraylar | $1,025 | $161,072119 claims |
| Alkermes, Inc.Lybalvi | $509 | $57,17834 claims |
| Axsome Therapeutics, Inc.Auvelity | $356 | $39,64042 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $64 | $19,84534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Cincinnati
- Terri PopovitzCincinnati$161K
- Michelle McBrideCincinnati$29K
- Seth FramptonCincinnati$10K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.